BTIG Downgrades Theravance Biopharma to Neutral

Benzinga Newsdesk www.benzinga.com Negative 89.4%

Neg 89.4% Neu 0% Pos 0%

BTIG analyst Julian Harrison downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Neutral.

Comments

No comments yet. Be the first!